December 16, 2024 06:20 AM EST

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Kyle LaHucik

Senior Reporter

Roche has officially discontinued a Phase 3 hemophilia A gene therapy from its Spark Therapeutics unit, a spokesperson for the Swiss pharma told Endpoints News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

Novo Nordisk to spend $1.2B for new rare disease drug factory in Denmark

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

CDK4 in­hibitors from BeiGene and Pfiz­er, ALX’s CD47 drug take the stage at SABCS

No­vo Nordisk to spend $1.2B for new rare dis­ease drug fac­to­ry in Den­mark

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

Novo Nordisk to spend $1.2B for new rare disease drug factory in Denmark

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary